Skip to content
Companies

Adela

Methylation blood tests for cancer monitoring

Raised to date

$5M

of $5M offered across 1 Form D filing

Investors
1
Last filed
Apr 23, 2026

About

Adela develops blood-based molecular tests for detecting and monitoring cancer. Its liquid-biopsy approach analyzes cell-free DNA using genome-wide methylation enrichment combined with computational analysis, so no tumor tissue sample is required. The company's first clinically validated application monitors patient response to immunotherapy in advanced solid tumors, with results published in NPJ Precision Oncology. The underlying methylation-enrichment technology was developed by co-founder and Chief Scientific Officer Dr. Daniel De Carvalho at University Health Network's Princess Margaret Cancer Centre; Adela operates from Foster City, California and Toronto, Canada.

Tissue-free, genome-wide methylation enrichment rather than targeted sequencing of a fixed mutation panel, so a single blood draw can be applied across the cancer continuum — early detection, diagnosis, and treatment monitoring — without needing a matched tumor biopsy.

Funding

  • DebtFiled Apr 23, 2026Form D
    $5M/ $5M

Product

Adela methylation-based blood test

Liquid biopsy diagnostic test

A liquid-biopsy test that reads genome-wide methylation patterns in cell-free DNA from a blood sample to identify cancer signals, used first for monitoring immunotherapy response in advanced solid tumors.

  • Genome-wide cell-free DNA methylation enrichment
  • Tissue-free: requires only a blood sample, no matched tumor biopsy
  • Computational analysis of epigenetic cancer signals

Built for

Oncologists and clinical care teams treating solid tumors, plus health systems adopting non-invasive molecular diagnostics

People on file